Corman C, Guberman A, Benavente O
Department of Pharmacy, Ottawa General Hospital, Ontario, Canada.
Seizure. 1998 Jun;7(3):243-7. doi: 10.1016/s1059-1311(98)80043-5.
Clobazam is the first and only 1,5-benzodiazepine to be used in the management of epilepsy. The use and effectiveness of oral clobazam in patients with status epilepticus has only been previously described in one study of 16 cases, seven of whom were in complex partial status. We have used clobazam in four patients with EEG-proven partial status epilepticus refractory to standard antiepileptic drugs. In all cases, except one, the seizure activity was controlled within 2 hr of administering clobazam. Our four patients responded promptly to an oral loading of clobazam which was approximately twice the usual daily maintenance dose. The drug was well tolerated and no adverse effects were seen. Clobazam's effectiveness as a first-line agent remains to be studied. Further controlled studies are recommended.
氯巴占是首个且唯一用于癫痫治疗的1,5-苯二氮䓬类药物。口服氯巴占在癫痫持续状态患者中的应用及有效性此前仅在一项16例患者的研究中有所描述，其中7例为复杂部分性癫痫持续状态。我们将氯巴占用于4例经脑电图证实的对标准抗癫痫药物难治的部分性癫痫持续状态患者。在所有病例中，除1例之外，癫痫发作活动在给予氯巴占后2小时内得到控制。我们的4例患者对口服负荷剂量氯巴占反应迅速，该负荷剂量约为通常每日维持剂量的两倍。该药物耐受性良好，未见不良反应。氯巴占作为一线药物的有效性仍有待研究。建议开展进一步的对照研究。
